Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety

201848 citationsJournal Articlebronze Open Access

Authors

Britt Christensen · Monash University

Ruben J. Colman · University of Chicago

Dejan Micić · University of Chicago

Peter G. Gibson · Monash University

Sarah R. Goeppinger · University of Chicago

Andrés Yarur · University of Chicago

Christopher R. Weber ·

Abstract

In this real-world study, vedolizumab demonstrated similar efficacy and safety seen in pivotal trials, with sustained clinical response in the majority of patients. Similar rates of response were seen in UC and CD patients. 10.1093/ibd/izx067_video1izx067_Video5754037470001.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Pregnancy and Medication Impact

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Inflammatory Bowel Diseases

Volume 24, Issue 4, pp. 849-860

DOI: 10.1093/ibd/izx067

Field-Weighted Citation Impact: 4.70